Yonsei Med J.  2018 Oct;59(8):945-950. 10.3349/ymj.2018.59.8.945.

Regulation of Colonic Mucosal MicroRNA Expression via Multiple Targets in Visceral Hypersensitivity Rats by Tongxieyaofang

• Chao G
• Wang Y
• Ye F
• Zhang S

• KMID: 2419728
• DOI: http://doi.org/10.3349/ymj.2018.59.8.945

Abstract

PURPOSE
This study aimed to screen for differentially expressed microRNAs (miRNAs) in the colons of rats with visceral hypersensitivity to build the expression profiles of miRNAs therein and to determine the mechanism of Tongxieyaofang use in the treatment of irritable bowel syndrome (IBS).
MATERIALS AND METHODS
Forty Sprague-Dawley rats were divided randomly into four groups: control group, model control group (induced by rectum stimulus and evaluated by abdominal withdraw reaction), treatment control group (normal saline), and Tongxieyaofang group (treated with Tongxieyaofang). We screened for differential expression of colonic mucosal miRNAs using liquid chip technology and verified the expression thereof using reverse transcription-PCR.
RESULTS
The visceral hypersensitivity rat model was successfully established. We found the expression of let-7f, let-7i, miR-130b, miR-29a, miR-132, miR-21, and miR-375 to be up-regulated (p < 0.05), while the expression of miR-24, miR-31a, miR-192, miR-221, and miR-223 was down-regulated (p < 0.05) in the visceral hypersensitivity rats. After treatment with Tongxieyaofang, the expression of let-7f, let-7i, miR-130b, miR-29a, miR-132, miR-21, and miR-375 was reduced (p < 0.05), whereas the expression of miR-24, miR-31a, miR-192, miR-221, miR-223 was increased, compared to the treatment control group (p < 0.05).
CONCLUSION
MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang.

Keyword

Visceral hypersensitivity; irritable bowel syndrome; microRNAs; Tongxieyaofang

MeSH Terms

Animals
Colon*
Hypersensitivity*
Irritable Bowel Syndrome
MicroRNAs*
Models, Animal
Rats*
Rats, Sprague-Dawley
Rectum
MicroRNAs

Figure

• 

  Fig. 1 Expression of miRNAs in the rat colon. Group 1, control group; Group 2, model control group; Group 3, treatment control group; Group 4, Tongxieyaofang group.

Reference

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006; 130:1480–1491. PMID: 16678561.

2. Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain. 2001; 93:7–14. PMID: 11406333.

3. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009; 146:41–46. PMID: 19595511.

4. Camilleri M, Nadeau A, Lamsam J, Nord SL, Ryks M, Burton D, et al. Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion. Neurogastroenterol Motil. 2010; 22:e15–e26. PMID: 19614866.

5. Zhou Q, Verne GN. New insights into visceral hypersensitivity--clinical implications in IBS. Nat Rev Gastroenterol Hepatol. 2011; 8:349–355. PMID: 21643039.

6. Zhou Q, Yang L, Larson S, Basra S, Merwat S, Tan A, et al. Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1. Gut. 2016; 65:797–805. PMID: 25681400.

7. Kim J, Krichevsky A, Grad Y, Hayes GD, Kosik KS, Church GM, et al. Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. Proc Natl Acad Sci U S A. 2004; 101:360–365. PMID: 14691248.

8. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9:775–789. PMID: 20885409.

9. Zhou Q, Souba WW, Croce CM, Verne GN. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut. 2010; 59:775–784. PMID: 19951903.

10. Liao XJ, Mao WM, Wang Q, Yang GG, Wu WJ, Shao SX. MicroRNA-24 inhibits serotonin reuptake transporter expression and aggravates irritable bowel syndrome. Biochem Biophys Res Commun. 2016; 469:288–293. PMID: 26631964.

11. Fourie NH, Peace RM, Abey SK, Sherwin LB, Rahim-Williams B, Smyser PA, et al. Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome. Exp Mol Pathol. 2014; 96:422–425. PMID: 24768587.

12. Yang QQ, Xu XP, Zhao HS, Cai YQ, Pan YM, Xu JQ, et al. Differential expression of microRNA related to irritable bowel syndrome in a rabbit model. J Dig Dis. 2017; 18:330–342. PMID: 28509372.

13. Johnston DGW, Williams MA, Thaiss CA, Cabrera-Rubio R, Raverdeau M, McEntee C, et al. Loss of microRNA-21 influences the gut microbiota, causing reduced susceptibility in a murine model of colitis. J Crohns Colitis. 2018; 12:835–848. PMID: 29608690.

14. Ma G, Dai W, Sang A, Yang X, Gao C. Upregulation of microRNA-23a/b promotes tumor progression and confers poor prognosis in patients with gastric cancer. Int J Clin Exp Pathol. 2014; 7:8833–8840. PMID: 25674252.

15. Xu X, Gao F, Wang J, Tao L, Ye J, Ding L, et al. MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4. Cancer Biol Ther. 2018; 19:427–435. PMID: 29509059.

16. Lin XT, Zheng XB, Fan DJ, Yao QQ, Hu JC, Lian L, et al. MicroRNA-143 targets ATG2B to inhibit autophagy and increase inflammatory responses in Crohn's disease. Inflamm Bowel Dis. 2018; 24:781–791. PMID: 29562274.

17. Kim H, Banerjee N, Sirven MA, Minamoto Y, Markel ME, Suchodolski JS, et al. Pomegranate polyphenolics reduce inflammation and ulceration in intestinal colitis-involvement of the miR-145/p70S6K1/HIF1α axis in vivo and in vitro. J Nutr Biochem. 2017; 43:107–115. PMID: 28282584.

18. Szuücs D, Béres NJ, Rokonay R, Boros K, Borka K, Kiss Z, et al. Increased duodenal expression of miR-146a and -155 in pediatric Crohn's disease. World J Gastroenterol. 2016; 22:6027–6035. PMID: 27468194.

19. Shen Y, Zhou M, Yan J, Gong Z, Xiao Y, Zhang C, et al. miR-200b inhibits TNF-α-induced IL-8 secretion and tight junction disruption of intestinal epithelial cells in vitro. Am J Physiol Gastrointest Liver Physiol. 2017; 312:G123–G132. PMID: 27979826.

20. Heckmann D, Maier P, Laufs S, Li L, Sleeman JP, Trunk MJ, et al. The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1α-induced gene expression, invasion and chemosensitivity of colon cancer. Clin Cancer Res. 2014; 20:604–616. PMID: 24255072.

21. Peck BC, Mah AT, Pitman WA, Ding S, Lund PK, Sethupathy P. Functional transcriptomics in diverse intestinal epithelial cell types reveals robust MicroRNA sensitivity in intestinal stem cells to microbial status. J Biol Chem. 2017; 292:2586–2600. PMID: 28053090.

22. Olaru AV, Selaru FM, Mori Y, Vazquez C, David S, Paun B, et al. Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflamm Bowel Dis. 2011; 17:221–231. PMID: 20848542.

23. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006; 130:1377–1390. PMID: 16678553.

24. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut. 2000; 46:78–82. PMID: 10601059.

25. Chang FY, Lu CL, Chen TS. The current prevalence of irritable bowel syndrome in Asia. J Neurogastroenterol Motil. 2010; 16:389–400. PMID: 21103420.

26. Corsetti M, Van Oudenhove L, Tack J. The quest for biomarkers in IBS-where should it lead us? Neurogastroenterol Motil. 2014; 26:1669–1676. PMID: 25424580.

27. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science. 2005; 310:1817–1821. PMID: 16308420.

28. Sima X, Sun H, Zhou P, You C. A potential polymorphism in the promoter of let-7 is associated with an increased risk of intracranial aneurysm: a case-control study. Medicine (Baltimore). 2015; 94:e2267. PMID: 26705209.

29. Sun Y, Jin X, Liu X, Zhang M, Liu W, Li Z, et al. MicroRNA let-7i regulates dendritic cells maturation targeting interleukin-10 via the Janus kinase 1-signal transducer and activator of transcription 3 signal pathway subsequently induces prolonged cardiac allograft survival in rats. J Heart Lung Transplant. 2016; 35:378–388. PMID: 26755202.

30. Davoodian N, Lotfi AS, Soleimani M, Mola SJ, Arjmand S. Let-7f microRNA negatively regulates hepatic differentiation of human adipose tissue-derived stem cells. J Physiol Biochem. 2014; 70:781–789. PMID: 25077652.

31. Li M, Zhang L, Lu B, Chen Z, Chu L, Meng L, et al. Role of dendritic cell-mediated abnormal immune response in visceral hypersensitivity. Int J Clin Exp Med. 2015; 8:13243–13250. PMID: 26550249.

32. Rieger JK, Reutter S, Hofmann U, Schwab M, Zanger UM. Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9. Drug Metab Dispos. 2015; 43:884–888. PMID: 25802328.

33. Salta E, Lau P, Sala Frigerio C, Coolen M, Bally-Cuif L, De Strooper B. A self-organizing miR-132/Ctbp2 circuit regulates bimodal notch signals and glial progenitor fate choice during spinal cord maturation. Dev Cell. 2014; 30:423–436. PMID: 25132384.

34. Chen WX, Ren LH, Shi RH. Implication of miRNAs for inflammatory bowel disease treatment: systematic review. World J Gastrointest Pathophysiol. 2014; 5:63–70. PMID: 24891977.

35. Mussnich P, Rosa R, Bianco R, Fusco A, D'Angelo D. MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets. 2015; 19:1017–1026. PMID: 26107137.

36. Bian Z, Wu T, Liu L, Miao J, Wong H, Song L, et al. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J Altern Complement Med. 2006; 12:401–407. PMID: 16722791.

37. Liao H, Banbury LK, Leach DN. Elucidation of danzhixiaoyao wan and its constituent herbs on antioxidant activity and inhibition of nitric oxide production. Evid Based Complement Alternat Med. 2007; 4:425–430. PMID: 18227909.

38. Hu XG, Xu D, Zhao Y, Yang XB, Meng J, Shen H, et al. The alleviating pain effect of aqueous extract from tong-xie-yao-fang, on experimental visceral hypersensitivity and its mechanism. Biol Pharm Bull. 2009; 32:1075–1079. PMID: 19483318.